Effect vs placebo Class NWMA | Effect vs placebo Sensitivity analysis | Rank | ||||||
Class | Median | 95% CrI | Median | 95% CrI | Mean | Median | 95% CrI | Pr (best) |
LABA/ICS | 100.80 | (55.50 to 140.10) | 100.00 | (53.77 to 141.50) | 1.7 | 1 | (1 to 3) | 0.5 |
LAMA | 92.64 | (56.23 to 129.60) | 94.23 | (56.08 to 134.30) | 2.0 | 2 | (1 to 3) | 0.3 |
LABA | 87.05 | (47.28 to 130.50) | 86.88 | (46.12 to 132.00) | 2.3 | 2 | (1 to 3) | 0.2 |
ICS | 28.36 | (‐11.93 to 65.70) | 28.00 | (‐13.34 to 66.90) | 4.1 | 4 | (4 to 5) | 0.0 |
aFor effects versus placebo, smaller values indicate larger benefits of the active treatment. Crl = credible interval. FEV1 = forced expiratory volume in one second. ICS = inhaled corticosteroid. LABA = long‐acting beta2‐agonist. LABA/ICS = long‐acting beta2‐agonist/inhaled corticosteroid. LAMA = long‐acting antimuscarinic antagonist. NWMA = network meta‐analysis. Pr = probability. |